Trials / Withdrawn
WithdrawnNCT04379492
A Study of Hydroxycholoroquine Compared to Placebo as Treatment for People With COVID-19
Single-center, Phase II, Randomized Double-blind, Placebo-controlled Study of Hydroxychloroquine Compared to Placebo as Treatment for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is being done to see if hydroxychloroquine is an effective treatment for COVID-19.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Hydroxychloroquine | Participants will receive hydroxycholoroquine (200-mg tablets) 2 tablets orally q12h for 2 doses on day 1 (load), followed by 1 tablet orally q12h for days 2-5. |
| OTHER | Placebo | Participants will receive masked placebo given as 2 tablets orally q12h for 2 doses on day 1, followed by 1 tablet orally q12h for days 2-5. |
Timeline
- Start date
- 2020-05-05
- Primary completion
- 2020-09-25
- Completion
- 2020-09-25
- First posted
- 2020-05-07
- Last updated
- 2025-05-16
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04379492. Inclusion in this directory is not an endorsement.